{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "20",
                "@timestamp": "2022-03-20T22:14:13.000013-04:00",
                "@year": "2022",
                "@month": "03"
            },
            "ait:date-sort": {
                "@day": "08",
                "@year": "2022",
                "@month": "03"
            }
        },
        "xocs:meta": {"xocs:funding-list": {
            "@pui-match": "primary",
            "@has-funding-info": "1",
            "xocs:funding": [
                {
                    "xocs:funding-agency-matched-string": "National Institutes of Health",
                    "xocs:funding-agency-acronym": "NIH",
                    "xocs:funding-agency": "National Institutes of Health",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100000002",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "National Cancer Institute",
                    "xocs:funding-agency-acronym": "NCI",
                    "xocs:funding-agency": "National Cancer Institute",
                    "xocs:funding-id": [
                        {"$": "P30 CA008748"},
                        {"$": "R42 CA254685-01"}
                    ],
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100000054",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Amgen",
                    "xocs:funding-agency": "Amgen",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100002429",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "National Center for Advancing Translational Sciences",
                    "xocs:funding-agency-acronym": "NCATS",
                    "xocs:funding-agency": "National Center for Advancing Translational Sciences",
                    "xocs:funding-id": "P01 CA23766",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100006108",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Actinium Pharmaceuticals",
                    "xocs:funding-agency-acronym": "ATNM",
                    "xocs:funding-agency": "Actinium Pharmaceuticals",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100010535",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                }
            ],
            "xocs:funding-addon-generated-timestamp": "2022-03-16T00:55:59.429Z",
            "xocs:funding-text": [
                {"$": "Conflict-of-interest disclosure: A.C.K. serves on a scientific advisory board for Astellas; and has received consulting fees from AbbVie. M.B.G. receives research support from Amgen, Actinium Pharmaceuticals, and the National Cancer Institute (R42 CA254685-01); and serves in an advisory role for Sanofi. B.G. reports research funding for a clinical trial from Actinium Pharma. M.-A.P. reports honoraria from Kite/Gilead, AbbVie, Bellicum, Bristol Myers Squibb, Incyte, Merck, Novartis, Nektar Therapeutics, Omeros, and Takeda; serves on Data and Safety Monitoring Boards"},
                {"$": "Thailand. This study is supported in part by the National Institutes of Health, National Center for Advancing Translational Sciences award P01 CA23766, and National Cancer Institute Cancer Center Support grant P30 CA008748."}
            ],
            "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"
        }},
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60009343",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Adult BMT Service"},
                                {"$": "Department of Medicine"},
                                {"$": "Memorial Sloan Kettering Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60009343",
                                "@dptid": "109501192"
                            },
                            "state": "NY",
                            "@affiliation-instance-id": "2017182415-1bae566206261e6fafb62c3f5654c8c5",
                            "ce:source-text": "Adult BMT Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;",
                            "@dptid": "109501192"
                        },
                        "author": [
                            {
                                "ce:given-name": "Kitsada",
                                "preferred-name": {
                                    "ce:given-name": "Kitsada",
                                    "ce:initials": "K.",
                                    "ce:surname": "Wudhikarn",
                                    "ce:indexed-name": "Wudhikarn K."
                                },
                                "@author-instance-id": "2017182415-d7a25d8a02d7e8516a087bd5557b10ae",
                                "@seq": "1",
                                "ce:initials": "K.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Wudhikarn",
                                "@auid": "37091810400",
                                "ce:indexed-name": "Wudhikarn K."
                            },
                            {
                                "ce:given-name": "Boglarka",
                                "preferred-name": {
                                    "ce:given-name": "Boglarka",
                                    "ce:initials": "B.",
                                    "ce:surname": "Gyurkocza",
                                    "ce:indexed-name": "Gyurkocza B."
                                },
                                "@author-instance-id": "2017182415-0e743c0369d8091a1605f1b939cca7cf",
                                "@seq": "6",
                                "ce:initials": "B.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Gyurkocza",
                                "@auid": "57197752257",
                                "ce:indexed-name": "Gyurkocza B."
                            },
                            {
                                "ce:given-name": "Miguel-Angel",
                                "preferred-name": {
                                    "ce:given-name": "Miguel Angel",
                                    "ce:initials": "M.A.",
                                    "ce:surname": "Perales",
                                    "ce:indexed-name": "Perales M.A."
                                },
                                "@author-instance-id": "2017182415-8cf94690a63959cf25ecc7114a68c5e8",
                                "@seq": "7",
                                "ce:initials": "M.-A.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Perales",
                                "@auid": "6701893624",
                                "@orcid": "0000-0002-5910-4571",
                                "ce:indexed-name": "Perales M.-A."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60002620",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Division of Hematology and Research Unit in Translational Hematology"},
                                {"$": "Department of Medicine"},
                                {"$": "Chulalongkorn University"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60002620",
                                    "@dptid": "126210793"
                                },
                                {"@afid": "60028190"}
                            ],
                            "@affiliation-instance-id": "2017182415-53caedf1219aa1e3358f0e7bef4ccc88",
                            "ce:source-text": "Division of Hematology and Research Unit in Translational Hematology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand;",
                            "@dptid": "126210793"
                        },
                        "author": [{
                            "ce:given-name": "Kitsada",
                            "preferred-name": {
                                "ce:given-name": "Kitsada",
                                "ce:initials": "K.",
                                "ce:surname": "Wudhikarn",
                                "ce:indexed-name": "Wudhikarn K."
                            },
                            "@author-instance-id": "2017182415-d7a25d8a02d7e8516a087bd5557b10ae",
                            "@seq": "1",
                            "ce:initials": "K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Wudhikarn",
                            "@auid": "37091810400",
                            "ce:indexed-name": "Wudhikarn K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60009343",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Leukemia Service"},
                                {"$": "Department of Medicine"},
                                {"$": "Memorial Sloan Kettering Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60009343",
                                "@dptid": "109501192"
                            },
                            "state": "NY",
                            "@affiliation-instance-id": "2017182415-0164611c2d14c0aebc9dc6dda4863bc9",
                            "ce:source-text": "Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;",
                            "@dptid": "109501192"
                        },
                        "author": [
                            {
                                "ce:given-name": "Amber C.",
                                "preferred-name": {
                                    "ce:given-name": "Amber C.",
                                    "ce:initials": "A.C.",
                                    "ce:surname": "King",
                                    "ce:indexed-name": "King A.C."
                                },
                                "@author-instance-id": "2017182415-b4577fe8b5c083a26a5013e2e8d60ab4",
                                "@seq": "2",
                                "ce:initials": "A.C.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "King",
                                "@auid": "57191189083",
                                "@orcid": "0000-0002-4333-9624",
                                "ce:indexed-name": "King A.C."
                            },
                            {
                                "ce:given-name": "Mark B.",
                                "preferred-name": {
                                    "ce:given-name": "Mark B.",
                                    "ce:initials": "M.B.",
                                    "ce:surname": "Geyer",
                                    "ce:indexed-name": "Geyer M.B."
                                },
                                "@author-instance-id": "2017182415-b28c5b180208eff4860d184cdc72d360",
                                "@seq": "3",
                                "ce:initials": "M.B.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Geyer",
                                "@auid": "43561336800",
                                "ce:indexed-name": "Geyer M.B."
                            },
                            {
                                "ce:given-name": "Yvette",
                                "preferred-name": {
                                    "ce:given-name": "Yvette",
                                    "ce:initials": "Y.",
                                    "ce:surname": "Bernal",
                                    "ce:indexed-name": "Bernal Y."
                                },
                                "@author-instance-id": "2017182415-301ceb51e48a2e1ef45482e4f699433f",
                                "@seq": "5",
                                "ce:initials": "Y.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Bernal",
                                "@auid": "36192617400",
                                "ce:indexed-name": "Bernal Y."
                            },
                            {
                                "ce:given-name": "Jae H.",
                                "preferred-name": {
                                    "ce:given-name": "Jae H.",
                                    "ce:initials": "J.H.",
                                    "ce:surname": "Park",
                                    "ce:indexed-name": "Park J.H."
                                },
                                "@author-instance-id": "2017182415-2095ec3fdc55c0cbd509116036a9f897",
                                "@seq": "8",
                                "ce:initials": "J.H.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Park",
                                "@auid": "45561459900",
                                "ce:indexed-name": "Park J.H."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60007997",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Department of Medicine"},
                                {"$": "Weill Cornell Medical College of Cornell University"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60007997",
                                    "@dptid": "112748380"
                                },
                                {"@afid": "60007776"}
                            ],
                            "state": "NY",
                            "@affiliation-instance-id": "2017182415-afa1c388096199d732daff5e69749958",
                            "ce:source-text": "Department of Medicine, Weill Cornell Medical College of Cornell University, New York, NY; and",
                            "@dptid": "112748380"
                        },
                        "author": [
                            {
                                "ce:given-name": "Mark B.",
                                "preferred-name": {
                                    "ce:given-name": "Mark B.",
                                    "ce:initials": "M.B.",
                                    "ce:surname": "Geyer",
                                    "ce:indexed-name": "Geyer M.B."
                                },
                                "@author-instance-id": "2017182415-b28c5b180208eff4860d184cdc72d360",
                                "@seq": "3",
                                "ce:initials": "M.B.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Geyer",
                                "@auid": "43561336800",
                                "ce:indexed-name": "Geyer M.B."
                            },
                            {
                                "ce:given-name": "Boglarka",
                                "preferred-name": {
                                    "ce:given-name": "Boglarka",
                                    "ce:initials": "B.",
                                    "ce:surname": "Gyurkocza",
                                    "ce:indexed-name": "Gyurkocza B."
                                },
                                "@author-instance-id": "2017182415-0e743c0369d8091a1605f1b939cca7cf",
                                "@seq": "6",
                                "ce:initials": "B.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Gyurkocza",
                                "@auid": "57197752257",
                                "ce:indexed-name": "Gyurkocza B."
                            },
                            {
                                "ce:given-name": "Miguel-Angel",
                                "preferred-name": {
                                    "ce:given-name": "Miguel Angel",
                                    "ce:initials": "M.A.",
                                    "ce:surname": "Perales",
                                    "ce:indexed-name": "Perales M.A."
                                },
                                "@author-instance-id": "2017182415-8cf94690a63959cf25ecc7114a68c5e8",
                                "@seq": "7",
                                "ce:initials": "M.-A.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Perales",
                                "@auid": "6701893624",
                                "@orcid": "0000-0002-5910-4571",
                                "ce:indexed-name": "Perales M.-A."
                            },
                            {
                                "ce:given-name": "Jae H.",
                                "preferred-name": {
                                    "ce:given-name": "Jae H.",
                                    "ce:initials": "J.H.",
                                    "ce:surname": "Park",
                                    "ce:indexed-name": "Park J.H."
                                },
                                "@author-instance-id": "2017182415-2095ec3fdc55c0cbd509116036a9f897",
                                "@seq": "8",
                                "ce:initials": "J.H.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Park",
                                "@auid": "45561459900",
                                "ce:indexed-name": "Park J.H."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60009343",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Hematopathology Service"},
                                {"$": "Department of Pathology"},
                                {"$": "Memorial Sloan Kettering Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60009343",
                                "@dptid": "113226559"
                            },
                            "state": "NY",
                            "@affiliation-instance-id": "2017182415-7cddd9a5d2280c5736f0f511c86a207d",
                            "ce:source-text": "Hematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY",
                            "@dptid": "113226559"
                        },
                        "author": [{
                            "ce:given-name": "Mikhail",
                            "preferred-name": {
                                "ce:given-name": "Mikhail",
                                "ce:initials": "M.",
                                "ce:surname": "Roshal",
                                "ce:indexed-name": "Roshal M."
                            },
                            "@author-instance-id": "2017182415-3300f166bfa30b8548959f988a6d268f",
                            "@seq": "4",
                            "ce:initials": "M.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Roshal",
                            "@auid": "6506624002",
                            "ce:indexed-name": "Roshal M."
                        }]
                    }
                ],
                "citation-title": "Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab",
                "abstracts": "© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.Novel monoclonal antibody (mAb)-based therapies targeting CD19 and CD22 (blinatumomab and inotuzumab) have shown high rates of complete remission (CR) and been used as a bridging treatment to potentially curative allogeneic hematopoietic stem cell transplantation (alloHSCT) in adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). However, limited data exist on the outcome of patients resistant to both mAbs as well as responses to each agent when progressed after the alternate antigen-targeted mAb. Herein, we report outcomes of 29 patients with R/R B-ALL previously treated with both blinatumomab and inotuzumab. Twenty-five patients (86.2%) received blinatumomab as first mAb (mAb1), and CD19-negative/dim relapses were observed in 44% of the patients. Inotuzumab induced CR in 68% of the patients for post-blinatumomab relapse regardless of CD19 expression status. The median time between mAb1 and mAb2 was 99 days. Twelve (63.2%) of 19 patients who achieved remission after mAb2 underwent alloHSCT. The median time from mAb2 to alloHSCT was 37.5 days. Acute graft-versus-host disease and nonrelapse mortality were observed in 58.3% (grade 3 or higher, 25%) and 41.7%, respectively. With a median follow-up of 16.8 months after mAb2, 19 patients (65.5%) relapsed, and 21 patients (72.4%) have died. Overall survival was not different between alloHSCT and non-alloHSCT patients. In conclusion, patients with B-ALL who relapsed after blinatumomab could be successfully rescued by inotuzumab as a bridge to alloHSCT but represent an ultra-high-risk group with poor overall survival. Further studies, including novel consolidation and treatment sequence, may improve outcomes of these patients.",
                "correspondence": {
                    "affiliation": {
                        "country": "United States",
                        "postal-code": "10021",
                        "@country": "usa",
                        "city": "New York",
                        "organization": [
                            {"$": "Leukemia Service"},
                            {"$": "Department of Medicine"},
                            {"$": "Memorial Sloan Kettering Cancer Center"}
                        ],
                        "state": "NY",
                        "ce:source-text": "Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021;"
                    },
                    "person": {
                        "ce:given-name": "Jae H.",
                        "ce:initials": "J.H.",
                        "ce:surname": "Park",
                        "ce:indexed-name": "Park J.H."
                    }
                },
                "citation-info": {
                    "citation-type": {"@code": "ar"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "sourcetitle-abbrev": "Blood Adv.",
                    "website": {"ce:e-address": {
                        "$": "https://ashpublications.org/bloodadvances/article/6/5/1432/483549/Outcomes-of-relapsed-B-cell-acute-lymphoblastic",
                        "@type": "email"
                    }},
                    "@country": "usa",
                    "translated-sourcetitle": {"@xml:lang": "eng"},
                    "issn": [
                        {
                            "$": "24739537",
                            "@type": "electronic"
                        },
                        {
                            "$": "24739529",
                            "@type": "print"
                        }
                    ],
                    "volisspag": {
                        "voliss": {
                            "@volume": "6",
                            "@issue": "5"
                        },
                        "pagerange": {
                            "@first": "1432",
                            "@last": "1443"
                        }
                    },
                    "@type": "j",
                    "publicationyear": {"@first": "2022"},
                    "publisher": {"publishername": "American Society of Hematology"},
                    "sourcetitle": "Blood Advances",
                    "@srcid": "21100886825",
                    "publicationdate": {
                        "month": "03",
                        "year": "2022",
                        "date-text": {
                            "@xfab-added": "true",
                            "$": "8 March 2022"
                        },
                        "day": "08"
                    }
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "16",
                                    "classification-description": "Cancer"
                                },
                                {
                                    "classification-code": "25",
                                    "classification-description": "Hematology"
                                },
                                {
                                    "classification-code": "26",
                                    "classification-description": "Immunology, Serology and Transplantation"
                                },
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": "2720"
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": "MEDI"
                        }
                    ]},
                    "chemicalgroup": {"chemicals": {
                        "@source": "esbd",
                        "chemical": [
                            {
                                "cas-registry-number": "853426-35-4",
                                "chemical-name": "blinatumomab"
                            },
                            {
                                "cas-registry-number": "635715-01-4",
                                "chemical-name": "inotuzumab ozogamicin"
                            }
                        ]
                    }}
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2022 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "external-source": "In-Data-Review",
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "MEDL"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "19",
                    "@timestamp": "BST 07:23:35",
                    "@year": "2022",
                    "@month": "03"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2017182415",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "637076907",
                            "@idtype": "associatedPUI"
                        },
                        {
                            "$": "939027639",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20220224681",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "35042232",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "20220695892",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20220904075",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "20229004960237",
                            "@idtype": "TPA-ID"
                        },
                        {
                            "$": "85126133638",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85126133638",
                            "@idtype": "SGR"
                        }
                    ],
                    "ce:doi": "10.1182/bloodadvances.2021005978"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "29",
                "reference": [
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Oriol A, Vives S, Hernandez-Rivas JM, et al; Programa Español de Tratamiento en Hematologia Group. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010; 95(4):589-596.",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-title": {"ref-titletext": "Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group"},
                            "refd-itemidlist": {"itemid": {
                                "$": "77950664722",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "95",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "589",
                                    "@last": "596"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Oriol",
                                        "ce:indexed-name": "Oriol A"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Vives",
                                        "ce:indexed-name": "Vives S"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "JM",
                                        "@_fa": "true",
                                        "ce:surname": "Hernandez-Rivas",
                                        "ce:indexed-name": "Hernandez-Rivas JM"
                                    }
                                ],
                                "collaboration": {
                                    "@seq": "4",
                                    "ce:text": "Programa Español de Tratamiento en Hematologia Group",
                                    "ce:indexed-name": "Programa Espanol de Tratamiento en Hematologia Group"
                                },
                                "et-al": null
                            },
                            "ref-sourcetitle": "Haematologica"
                        },
                        "ce:source-text": "Oriol A, Vives S, Hernandez-Rivas JM, et al; Programa Español de Tratamiento en Hematologia Group. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010; 95(4):589-596."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Fielding AK, Richards SM, Chopra R, et al; Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944-950.",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2007"},
                            "ref-title": {"ref-titletext": "Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "33846869976",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "109",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "944",
                                    "@last": "950"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "AK",
                                        "@_fa": "true",
                                        "ce:surname": "Fielding",
                                        "ce:indexed-name": "Fielding AK"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "SM",
                                        "@_fa": "true",
                                        "ce:surname": "Richards",
                                        "ce:indexed-name": "Richards SM"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R",
                                        "@_fa": "true",
                                        "ce:surname": "Chopra",
                                        "ce:indexed-name": "Chopra R"
                                    }
                                ],
                                "collaboration": {
                                    "@seq": "4",
                                    "ce:text": "Eastern Cooperative Oncology Group",
                                    "ce:indexed-name": "Eastern Cooperative Oncology Group"
                                },
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Fielding AK, Richards SM, Chopra R, et al; Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944-950."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "DeFilipp Z, Advani AS, Bachanova V, et al. Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 evidence-based review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019;25(11): 2113-2123.",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 evidence-based review from the American Society for Transplantation and Cellular Therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85072529654",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "25",
                                    "@issue": "11"
                                },
                                "pagerange": {
                                    "@first": "2113",
                                    "@last": "2123"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Z",
                                        "@_fa": "true",
                                        "ce:surname": "DeFilipp",
                                        "ce:indexed-name": "DeFilipp Z"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "AS",
                                        "@_fa": "true",
                                        "ce:surname": "Advani",
                                        "ce:indexed-name": "Advani AS"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "V",
                                        "@_fa": "true",
                                        "ce:surname": "Bachanova",
                                        "ce:indexed-name": "Bachanova V"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transplant"
                        },
                        "ce:source-text": "DeFilipp Z, Advani AS, Bachanova V, et al. Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 evidence-based review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019;25(11): 2113-2123."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740-753.",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84984677465",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "375",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "740",
                                    "@last": "753"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "HM",
                                        "@_fa": "true",
                                        "ce:surname": "Kantarjian",
                                        "ce:indexed-name": "Kantarjian HM"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "DJ",
                                        "@_fa": "true",
                                        "ce:surname": "DeAngelo",
                                        "ce:indexed-name": "DeAngelo DJ"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Stelljes",
                                        "ce:indexed-name": "Stelljes M"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740-753."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Gokbuget \u20ac N, Kelsh M, Chia V, et al. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J. 2016;6(9):e473.",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85014429789",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "6",
                                    "@issue": "9"
                                },
                                "pagerange": {"@first": "e473"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N",
                                        "@_fa": "true",
                                        "ce:surname": "Gokbuget \u20ac",
                                        "ce:indexed-name": "Gokbuget \u20ac N"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Kelsh",
                                        "ce:indexed-name": "Kelsh M"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "V",
                                        "@_fa": "true",
                                        "ce:surname": "Chia",
                                        "ce:indexed-name": "Chia V"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Cancer J"
                        },
                        "ce:source-text": "Gokbuget \u20ac N, Kelsh M, Chia V, et al. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J. 2016;6(9):e473."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Topp MS, Gokbuget \u20ac N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134-4140.",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84916639631",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "32",
                                    "@issue": "36"
                                },
                                "pagerange": {
                                    "@first": "4134",
                                    "@last": "4140"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "MS",
                                        "@_fa": "true",
                                        "ce:surname": "Topp",
                                        "ce:indexed-name": "Topp MS"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N",
                                        "@_fa": "true",
                                        "ce:surname": "Gokbuget \u20ac",
                                        "ce:indexed-name": "Gokbuget \u20ac N"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G",
                                        "@_fa": "true",
                                        "ce:surname": "Zugmaier",
                                        "ce:indexed-name": "Zugmaier G"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Topp MS, Gokbuget \u20ac N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134-4140."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Badar T, Szabo A, Dinner S, et al. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021;127(7):1039-1048.",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85096971225",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "127",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "1039",
                                    "@last": "1048"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T",
                                        "@_fa": "true",
                                        "ce:surname": "Badar",
                                        "ce:indexed-name": "Badar T"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Szabo",
                                        "ce:indexed-name": "Szabo A"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Dinner",
                                        "ce:indexed-name": "Dinner S"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer"
                        },
                        "ce:source-text": "Badar T, Szabo A, Dinner S, et al. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021;127(7):1039-1048."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Geyer MB, Ritchie EK, Rao AV, et al. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica. 2021; 106(8):2086-2094.",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85093538535",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "106",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "2086",
                                    "@last": "2094"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "MB",
                                        "@_fa": "true",
                                        "ce:surname": "Geyer",
                                        "ce:indexed-name": "Geyer MB"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "EK",
                                        "@_fa": "true",
                                        "ce:surname": "Ritchie",
                                        "ce:indexed-name": "Ritchie EK"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "AV",
                                        "@_fa": "true",
                                        "ce:surname": "Rao",
                                        "ce:indexed-name": "Rao AV"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Haematologica"
                        },
                        "ce:source-text": "Geyer MB, Ritchie EK, Rao AV, et al. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica. 2021; 106(8):2086-2094."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Aldoss I, Song J, Stiller T, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2017;92(9):858-865.",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85026415224",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "92",
                                    "@issue": "9"
                                },
                                "pagerange": {
                                    "@first": "858",
                                    "@last": "865"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "I",
                                        "@_fa": "true",
                                        "ce:surname": "Aldoss",
                                        "ce:indexed-name": "Aldoss I"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Song",
                                        "ce:indexed-name": "Song J"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T",
                                        "@_fa": "true",
                                        "ce:surname": "Stiller",
                                        "ce:indexed-name": "Stiller T"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Am J Hematol"
                        },
                        "ce:source-text": "Aldoss I, Song J, Stiller T, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2017;92(9):858-865."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Dolan JG, Paessler ME, Rheingold SR, Pillai V. Hematopathologic correlates of CAR T-cell therapy. Clin Lab Med. 2021;41(3):325-339.",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Hematopathologic correlates of CAR T-cell therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85109949080",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "41",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "325",
                                    "@last": "339"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "JG",
                                    "@_fa": "true",
                                    "ce:surname": "Dolan",
                                    "ce:indexed-name": "Dolan JG"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "ME",
                                    "@_fa": "true",
                                    "ce:surname": "Paessler",
                                    "ce:indexed-name": "Paessler ME"
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "SR",
                                    "@_fa": "true",
                                    "ce:surname": "Rheingold",
                                    "ce:indexed-name": "Rheingold SR"
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "V.",
                                    "@_fa": "true",
                                    "ce:surname": "Pillai",
                                    "ce:indexed-name": "Pillai V."
                                }
                            ]},
                            "ref-sourcetitle": "Clin Lab Med"
                        },
                        "ce:source-text": "Dolan JG, Paessler ME, Rheingold SR, Pillai V. Hematopathologic correlates of CAR T-cell therapy. Clin Lab Med. 2021;41(3):325-339."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-828.",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "1995"},
                            "ref-title": {"ref-titletext": "1994 Consensus conference on acute GVHD grading"},
                            "refd-itemidlist": {"itemid": {
                                "$": "0029029246",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "15",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "825",
                                    "@last": "828"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D",
                                        "@_fa": "true",
                                        "ce:surname": "Przepiorka",
                                        "ce:indexed-name": "Przepiorka D"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D",
                                        "@_fa": "true",
                                        "ce:surname": "Weisdorf",
                                        "ce:indexed-name": "Weisdorf D"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P",
                                        "@_fa": "true",
                                        "ce:surname": "Martin",
                                        "ce:indexed-name": "Martin P"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Bone Marrow Transplant"
                        },
                        "ce:source-text": "Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-828."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-638.",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85062342961",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "25",
                                    "@issue": "4"
                                },
                                "pagerange": {
                                    "@first": "625",
                                    "@last": "638"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "DW",
                                        "@_fa": "true",
                                        "ce:surname": "Lee",
                                        "ce:indexed-name": "Lee DW"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "BD",
                                        "@_fa": "true",
                                        "ce:surname": "Santomasso",
                                        "ce:indexed-name": "Santomasso BD"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "FL",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke FL"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transplant"
                        },
                        "ce:source-text": "Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-638."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Mohty M, Malard F, Abecassis M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906-912.",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84968571756",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "51",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "906",
                                    "@last": "912"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Mohty",
                                        "ce:indexed-name": "Mohty M"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F",
                                        "@_fa": "true",
                                        "ce:surname": "Malard",
                                        "ce:indexed-name": "Malard F"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Abecassis",
                                        "ce:indexed-name": "Abecassis M"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Bone Marrow Transplant"
                        },
                        "ce:source-text": "Mohty M, Malard F, Abecassis M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906-912."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Topp MS, Stein AS, Gokbuget \u20ac N, et al. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: results of a pooled analysis. Cancer Med. 2021;10(8):2601-2610.",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: results of a pooled analysis"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85102712157",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "10",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "2601",
                                    "@last": "2610"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "MS",
                                        "@_fa": "true",
                                        "ce:surname": "Topp",
                                        "ce:indexed-name": "Topp MS"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "AS",
                                        "@_fa": "true",
                                        "ce:surname": "Stein",
                                        "ce:indexed-name": "Stein AS"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N",
                                        "@_fa": "true",
                                        "ce:surname": "Gokbuget \u20ac",
                                        "ce:indexed-name": "Gokbuget \u20ac N"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer Med"
                        },
                        "ce:source-text": "Topp MS, Stein AS, Gokbuget \u20ac N, et al. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: results of a pooled analysis. Cancer Med. 2021;10(8):2601-2610."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Jabbour E, Dull \u20ac J, Yilmaz M, et al. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: no change in the level of CD19 expression. Am J Hematol. 2018;93(3):371-374.",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: no change in the level of CD19 expression"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85038912620",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "93",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "371",
                                    "@last": "374"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E",
                                        "@_fa": "true",
                                        "ce:surname": "Jabbour",
                                        "ce:indexed-name": "Jabbour E"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J",
                                        "@_fa": "true",
                                        "ce:surname": "Dull \u20ac",
                                        "ce:indexed-name": "Dull \u20ac J"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Yilmaz",
                                        "ce:indexed-name": "Yilmaz M"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Am J Hematol"
                        },
                        "ce:source-text": "Jabbour E, Dull \u20ac J, Yilmaz M, et al. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: no change in the level of CD19 expression. Am J Hematol. 2018;93(3):371-374."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Rayes A, McMasters RL, O\u2019Brien MM. Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr Blood Cancer. 2016;63(6):1113-1115.",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84959387711",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "63",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "1113",
                                    "@last": "1115"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "A",
                                    "@_fa": "true",
                                    "ce:surname": "Rayes",
                                    "ce:indexed-name": "Rayes A"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "RL",
                                    "@_fa": "true",
                                    "ce:surname": "McMasters",
                                    "ce:indexed-name": "McMasters RL"
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "MM.",
                                    "@_fa": "true",
                                    "ce:surname": "O\u2019Brien",
                                    "ce:indexed-name": "O'Brien MM."
                                }
                            ]},
                            "ref-sourcetitle": "Pediatr Blood Cancer"
                        },
                        "ce:source-text": "Rayes A, McMasters RL, O\u2019Brien MM. Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr Blood Cancer. 2016;63(6):1113-1115."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J. 2016;14: 357-362.",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84991501323",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "14"},
                                "pagerange": {
                                    "@first": "357",
                                    "@last": "362"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "M",
                                    "@_fa": "true",
                                    "ce:surname": "Ruella",
                                    "ce:indexed-name": "Ruella M"
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "MV.",
                                    "@_fa": "true",
                                    "ce:surname": "Maus",
                                    "ce:indexed-name": "Maus MV."
                                }
                            ]},
                            "ref-sourcetitle": "Comput Struct Biotechnol J"
                        },
                        "ce:source-text": "Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J. 2016;14: 357-362."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Gokbuget \u20ac N, Dombret H, Ribera JM, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524-1533.",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85002157898",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "101",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "1524",
                                    "@last": "1533"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N",
                                        "@_fa": "true",
                                        "ce:surname": "Gokbuget \u20ac",
                                        "ce:indexed-name": "Gokbuget \u20ac N"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H",
                                        "@_fa": "true",
                                        "ce:surname": "Dombret",
                                        "ce:indexed-name": "Dombret H"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "JM",
                                        "@_fa": "true",
                                        "ce:surname": "Ribera",
                                        "ce:indexed-name": "Ribera JM"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Haematologica"
                        },
                        "ce:source-text": "Gokbuget \u20ac N, Dombret H, Ribera JM, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524-1533."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "O\u2019Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008;113(11): 3186-3191.",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2008"},
                            "ref-title": {"ref-titletext": "Outcome of adults with acute lymphocytic leukemia after second salvage therapy"},
                            "refd-itemidlist": {"itemid": {
                                "$": "58149394138",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "113",
                                    "@issue": "11"
                                },
                                "pagerange": {
                                    "@first": "3186",
                                    "@last": "3191"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "O\u2019Brien",
                                        "ce:indexed-name": "O'Brien S"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D",
                                        "@_fa": "true",
                                        "ce:surname": "Thomas",
                                        "ce:indexed-name": "Thomas D"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F",
                                        "@_fa": "true",
                                        "ce:surname": "Ravandi",
                                        "ce:indexed-name": "Ravandi F"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer"
                        },
                        "ce:source-text": "O\u2019Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008;113(11): 3186-3191."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Badar T, Szabo A, Advani A, et al. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Adv. 2020;4(10):2308-2316.",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85086878601",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "4",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "2308",
                                    "@last": "2316"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T",
                                        "@_fa": "true",
                                        "ce:surname": "Badar",
                                        "ce:indexed-name": "Badar T"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Szabo",
                                        "ce:indexed-name": "Szabo A"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Advani",
                                        "ce:indexed-name": "Advani A"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Badar T, Szabo A, Advani A, et al. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Adv. 2020;4(10):2308-2316."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Marks DI, Kebriaei P, Stelljes M, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2019;25(9):1720-1729.",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85066080694",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "25",
                                    "@issue": "9"
                                },
                                "pagerange": {
                                    "@first": "1720",
                                    "@last": "1729"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "DI",
                                        "@_fa": "true",
                                        "ce:surname": "Marks",
                                        "ce:indexed-name": "Marks DI"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P",
                                        "@_fa": "true",
                                        "ce:surname": "Kebriaei",
                                        "ce:indexed-name": "Kebriaei P"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M",
                                        "@_fa": "true",
                                        "ce:surname": "Stelljes",
                                        "ce:indexed-name": "Stelljes M"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transplant"
                        },
                        "ce:source-text": "Marks DI, Kebriaei P, Stelljes M, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2019;25(9):1720-1729."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Salhotra A, Yang D, Mokhtari S, et al. Outcomes of allogeneic hematopoietic cell transplantation after salvage therapy with blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2020;26(6):1084-1090.",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Outcomes of allogeneic hematopoietic cell transplantation after salvage therapy with blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85082857428",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "26",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "1084",
                                    "@last": "1090"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Salhotra",
                                        "ce:indexed-name": "Salhotra A"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D",
                                        "@_fa": "true",
                                        "ce:surname": "Yang",
                                        "ce:indexed-name": "Yang D"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S",
                                        "@_fa": "true",
                                        "ce:surname": "Mokhtari",
                                        "ce:indexed-name": "Mokhtari S"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transplant"
                        },
                        "ce:source-text": "Salhotra A, Yang D, Mokhtari S, et al. Outcomes of allogeneic hematopoietic cell transplantation after salvage therapy with blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2020;26(6):1084-1090."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "DeAngelo DJ, Advani AS, Marks DI, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020;10(8):81.",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85089196872",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "10",
                                    "@issue": "8"
                                },
                                "pagerange": {"@first": "81"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "DJ",
                                        "@_fa": "true",
                                        "ce:surname": "DeAngelo",
                                        "ce:indexed-name": "DeAngelo DJ"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "AS",
                                        "@_fa": "true",
                                        "ce:surname": "Advani",
                                        "ce:indexed-name": "Advani AS"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "DI",
                                        "@_fa": "true",
                                        "ce:surname": "Marks",
                                        "ce:indexed-name": "Marks DI"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Cancer J"
                        },
                        "ce:source-text": "DeAngelo DJ, Advani AS, Marks DI, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020;10(8):81."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Jabbour EJ, Gokbuget \u20ac N, Kantarjian HM, et al. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 2019;125(23):4181-4192.",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85070895923",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "125",
                                    "@issue": "23"
                                },
                                "pagerange": {
                                    "@first": "4181",
                                    "@last": "4192"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "EJ",
                                        "@_fa": "true",
                                        "ce:surname": "Jabbour",
                                        "ce:indexed-name": "Jabbour EJ"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N",
                                        "@_fa": "true",
                                        "ce:surname": "Gokbuget \u20ac",
                                        "ce:indexed-name": "Gokbuget \u20ac N"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "HM",
                                        "@_fa": "true",
                                        "ce:surname": "Kantarjian",
                                        "ce:indexed-name": "Kantarjian HM"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cancer"
                        },
                        "ce:source-text": "Jabbour EJ, Gokbuget \u20ac N, Kantarjian HM, et al. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 2019;125(23):4181-4192."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Sasaki K, Kantarjian HM, Ravandi F, et al. Sequential combination of inotuzumab ozogamicin (InO) with low-intensity chemotherapy (mini-hyper-CVD) with or without blinatumomab is highly effective in patients (pts) with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in first relapse. Blood. 2019;134(suppl 1):3806.",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Sequential combination of inotuzumab ozogamicin (InO) with low-intensity chemotherapy (mini-hyper-CVD) with or without blinatumomab is highly effective in patients (pts) with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in first relapse"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85082113412",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {"@volume": "134"},
                                "pagerange": {"@first": "3806"}
                            },
                            "ref-text": "(suppl 1)",
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K",
                                        "@_fa": "true",
                                        "ce:surname": "Sasaki",
                                        "ce:indexed-name": "Sasaki K"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "HM",
                                        "@_fa": "true",
                                        "ce:surname": "Kantarjian",
                                        "ce:indexed-name": "Kantarjian HM"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "F",
                                        "@_fa": "true",
                                        "ce:surname": "Ravandi",
                                        "ce:indexed-name": "Ravandi F"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Sasaki K, Kantarjian HM, Ravandi F, et al. Sequential combination of inotuzumab ozogamicin (InO) with low-intensity chemotherapy (mini-hyper-CVD) with or without blinatumomab is highly effective in patients (pts) with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in first relapse. Blood. 2019;134(suppl 1):3806."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Goldberg JD, Linker A, Kuk D, et al. T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(2): 208-213.",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease"},
                            "refd-itemidlist": {"itemid": {
                                "$": "84872508758",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "19",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "208",
                                    "@last": "213"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "JD",
                                        "@_fa": "true",
                                        "ce:surname": "Goldberg",
                                        "ce:indexed-name": "Goldberg JD"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Linker",
                                        "ce:indexed-name": "Linker A"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D",
                                        "@_fa": "true",
                                        "ce:surname": "Kuk",
                                        "ce:indexed-name": "Kuk D"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transplant"
                        },
                        "ce:source-text": "Goldberg JD, Linker A, Kuk D, et al. T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(2): 208-213."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Stelmach P, Wethmar K, Groth C, et al. Blinatumomab or inotuzumab ozogamicin as bridge to allogeneic stem cell transplantation for relapsed or refractory B-lineage acute lymphoblastic leukemia: a retrospective single-center analysis. Clin Lymphoma Myeloma Leuk. 2020;20(10):e724-e733.",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Blinatumomab or inotuzumab ozogamicin as bridge to allogeneic stem cell transplantation for relapsed or refractory B-lineage acute lymphoblastic leukemia: a retrospective single-center analysis"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85087483499",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "20",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "e724",
                                    "@last": "e733"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P",
                                        "@_fa": "true",
                                        "ce:surname": "Stelmach",
                                        "ce:indexed-name": "Stelmach P"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K",
                                        "@_fa": "true",
                                        "ce:surname": "Wethmar",
                                        "ce:indexed-name": "Wethmar K"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C",
                                        "@_fa": "true",
                                        "ce:surname": "Groth",
                                        "ce:indexed-name": "Groth C"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Lymphoma Myeloma Leuk"
                        },
                        "ce:source-text": "Stelmach P, Wethmar K, Groth C, et al. Blinatumomab or inotuzumab ozogamicin as bridge to allogeneic stem cell transplantation for relapsed or refractory B-lineage acute lymphoblastic leukemia: a retrospective single-center analysis. Clin Lymphoma Myeloma Leuk. 2020;20(10):e724-e733."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Kantarjian HM, DeAngelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4(8):e387-e398.",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85021846886",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "4",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "e387",
                                    "@last": "e398"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "HM",
                                        "@_fa": "true",
                                        "ce:surname": "Kantarjian",
                                        "ce:indexed-name": "Kantarjian HM"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "DJ",
                                        "@_fa": "true",
                                        "ce:surname": "DeAngelo",
                                        "ce:indexed-name": "DeAngelo DJ"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "AS",
                                        "@_fa": "true",
                                        "ce:surname": "Advani",
                                        "ce:indexed-name": "Advani AS"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Haematol"
                        },
                        "ce:source-text": "Kantarjian HM, DeAngelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4(8):e387-e398."
                    },
                    {
                        "@aii:was-generated-by": "http://data.elsevier.com/art/structure-references art:version v1.0.225",
                        "ref-fulltext": "Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491-502.",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study"},
                            "refd-itemidlist": {"itemid": {
                                "$": "85108290376",
                                "@idtype": "SGR"
                            }},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "398",
                                    "@issue": "10299"
                                },
                                "pagerange": {
                                    "@first": "491",
                                    "@last": "502"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "BD",
                                        "@_fa": "true",
                                        "ce:surname": "Shah",
                                        "ce:indexed-name": "Shah BD"
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A",
                                        "@_fa": "true",
                                        "ce:surname": "Ghobadi",
                                        "ce:indexed-name": "Ghobadi A"
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "OO",
                                        "@_fa": "true",
                                        "ce:surname": "Oluwole",
                                        "ce:indexed-name": "Oluwole OO"
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491-502."
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "New York",
            "@id": "60009343",
            "affilname": "Memorial Sloan-Kettering Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "New York",
            "@id": "60007997",
            "affilname": "Weill Cornell Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85126133638",
        "dc:description": "Novel monoclonal antibody (mAb)-based therapies targeting CD19 and CD22 (blinatumomab and inotuzumab) have shown high rates of complete remission (CR) and been used as a bridging treatment to potentially curative allogeneic hematopoietic stem cell transplantation (alloHSCT) in adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). However, limited data exist on the outcome of patients resistant to both mAbs as well as responses to each agent when progressed after the alternate antigen-targeted mAb. Herein, we report outcomes of 29 patients with R/R B-ALL previously treated with both blinatumomab and inotuzumab. Twenty-five patients (86.2%) received blinatumomab as first mAb (mAb1), and CD19-negative/dim relapses were observed in 44% of the patients. Inotuzumab induced CR in 68% of the patients for post-blinatumomab relapse regardless of CD19 expression status. The median time between mAb1 and mAb2 was 99 days. Twelve (63.2%) of 19 patients who achieved remission after mAb2 underwent alloHSCT. The median time from mAb2 to alloHSCT was 37.5 days. Acute graft-versus-host disease and nonrelapse mortality were observed in 58.3% (grade 3 or higher, 25%) and 41.7%, respectively. With a median follow-up of 16.8 months after mAb2, 19 patients (65.5%) relapsed, and 21 patients (72.4%) have died. Overall survival was not different between alloHSCT and non-alloHSCT patients. In conclusion, patients with B-ALL who relapsed after blinatumomab could be successfully rescued by inotuzumab as a bridge to alloHSCT but represent an ultra-high-risk group with poor overall survival. Further studies, including novel consolidation and treatment sequence, may improve outcomes of these patients.",
        "pubmed-id": "35042232",
        "prism:coverDate": "2022-03-08",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85126133638",
        "dc:creator": {"author": [{
            "ce:given-name": "Kitsada",
            "preferred-name": {
                "ce:given-name": "Kitsada",
                "ce:initials": "K.",
                "ce:surname": "Wudhikarn",
                "ce:indexed-name": "Wudhikarn K."
            },
            "@seq": "1",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60002620",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
                }
            ],
            "ce:surname": "Wudhikarn",
            "@auid": "37091810400",
            "author-url": "https://api.elsevier.com/content/author/author_id/37091810400",
            "ce:indexed-name": "Wudhikarn K."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85126133638"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85126133638&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85126133638&origin=inward"
            }
        ],
        "source-id": "21100886825",
        "citedby-count": "9",
        "prism:volume": "6",
        "subtype": "ar",
        "dc:title": "Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab",
        "openaccess": "1",
        "prism:issn": "24739537 24739529",
        "publishercopyright": "© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.",
        "prism:issueIdentifier": "5",
        "subtypeDescription": "Article",
        "prism:publicationName": "Blood Advances",
        "prism:pageRange": "1432-1443",
        "prism:endingPage": "1443",
        "openaccessFlag": "true",
        "prism:doi": "10.1182/bloodadvances.2021005978",
        "prism:startingPage": "1432",
        "dc:identifier": "SCOPUS_ID:85126133638",
        "dc:publisher": "American Society of Hematology"
    },
    "idxterms": null,
    "language": {"@xml:lang": "eng"},
    "authkeywords": null,
    "subject-areas": {"subject-area": [{
        "@_fa": "true",
        "$": "Hematology",
        "@code": "2720",
        "@abbrev": "MEDI"
    }]},
    "authors": {"author": [
        {
            "ce:given-name": "Kitsada",
            "preferred-name": {
                "ce:given-name": "Kitsada",
                "ce:initials": "K.",
                "ce:surname": "Wudhikarn",
                "ce:indexed-name": "Wudhikarn K."
            },
            "@seq": "1",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60002620",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
                }
            ],
            "ce:surname": "Wudhikarn",
            "@auid": "37091810400",
            "author-url": "https://api.elsevier.com/content/author/author_id/37091810400",
            "ce:indexed-name": "Wudhikarn K."
        },
        {
            "ce:given-name": "Amber C.",
            "preferred-name": {
                "ce:given-name": "Amber C.",
                "ce:initials": "A.C.",
                "ce:surname": "King",
                "ce:indexed-name": "King A.C."
            },
            "@seq": "2",
            "ce:initials": "A.C.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60009343",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
            },
            "ce:surname": "King",
            "@auid": "57191189083",
            "author-url": "https://api.elsevier.com/content/author/author_id/57191189083",
            "ce:indexed-name": "King A.C."
        },
        {
            "ce:given-name": "Mark B.",
            "preferred-name": {
                "ce:given-name": "Mark B.",
                "ce:initials": "M.B.",
                "ce:surname": "Geyer",
                "ce:indexed-name": "Geyer M.B."
            },
            "@seq": "3",
            "ce:initials": "M.B.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60007997",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997"
                }
            ],
            "ce:surname": "Geyer",
            "@auid": "43561336800",
            "author-url": "https://api.elsevier.com/content/author/author_id/43561336800",
            "ce:indexed-name": "Geyer M.B."
        },
        {
            "ce:given-name": "Mikhail",
            "preferred-name": {
                "ce:given-name": "Mikhail",
                "ce:initials": "M.",
                "ce:surname": "Roshal",
                "ce:indexed-name": "Roshal M."
            },
            "@seq": "4",
            "ce:initials": "M.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60009343",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
            },
            "ce:surname": "Roshal",
            "@auid": "6506624002",
            "author-url": "https://api.elsevier.com/content/author/author_id/6506624002",
            "ce:indexed-name": "Roshal M."
        },
        {
            "ce:given-name": "Yvette",
            "preferred-name": {
                "ce:given-name": "Yvette",
                "ce:initials": "Y.",
                "ce:surname": "Bernal",
                "ce:indexed-name": "Bernal Y."
            },
            "@seq": "5",
            "ce:initials": "Y.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60009343",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
            },
            "ce:surname": "Bernal",
            "@auid": "36192617400",
            "author-url": "https://api.elsevier.com/content/author/author_id/36192617400",
            "ce:indexed-name": "Bernal Y."
        },
        {
            "ce:given-name": "Boglarka",
            "preferred-name": {
                "ce:given-name": "Boglarka",
                "ce:initials": "B.",
                "ce:surname": "Gyurkocza",
                "ce:indexed-name": "Gyurkocza B."
            },
            "@seq": "6",
            "ce:initials": "B.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60007997",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997"
                }
            ],
            "ce:surname": "Gyurkocza",
            "@auid": "57197752257",
            "author-url": "https://api.elsevier.com/content/author/author_id/57197752257",
            "ce:indexed-name": "Gyurkocza B."
        },
        {
            "ce:given-name": "Miguel-Angel",
            "preferred-name": {
                "ce:given-name": "Miguel Angel",
                "ce:initials": "M.A.",
                "ce:surname": "Perales",
                "ce:indexed-name": "Perales M.A."
            },
            "@seq": "7",
            "ce:initials": "M.-A.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60007997",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997"
                }
            ],
            "ce:surname": "Perales",
            "@auid": "6701893624",
            "author-url": "https://api.elsevier.com/content/author/author_id/6701893624",
            "ce:indexed-name": "Perales M.-A."
        },
        {
            "ce:given-name": "Jae H.",
            "preferred-name": {
                "ce:given-name": "Jae H.",
                "ce:initials": "J.H.",
                "ce:surname": "Park",
                "ce:indexed-name": "Park J.H."
            },
            "@seq": "8",
            "ce:initials": "J.H.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60007997",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997"
                }
            ],
            "ce:surname": "Park",
            "@auid": "45561459900",
            "author-url": "https://api.elsevier.com/content/author/author_id/45561459900",
            "ce:indexed-name": "Park J.H."
        }
    ]}
}}